Valeant Pharma (VRX) Corrects adj.-EBITDA Guidance Lower to ~$6B on Call
Tweet
Share
E-mail
Get Alerts VRX Hot Sheet
Price: $23.40 --0%
Financial Fact:
Income from discontinued operations attributable to Valeant: 0
Today's EPS Names:
CCEL, FEIM, PLG, More
Financial Fact:
Income from discontinued operations attributable to Valeant: 0
Today's EPS Names:
CCEL, FEIM, PLG, More
Join SI Premium – FREE
Valeant Pharma (NYSE: VRX) corrected EBITDA guidance for the next four quarters to about $6 billion on its earning call. An earlier release forecast next four quarters (second quarter 2016 – first quarter 2017) guidance of about $6.2 - $6.6 billion.
Shares are lower by 36 percent.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rackspace cuts FY26 revenue outlook by $150M, expands AI plans
- Alignment Healthcare: Allegations Are Wholly Without Merit - Bloomberg
- Solaris Energy Infrastructure to Join S&P SmallCap 600
Create E-mail Alert Related Categories
Corporate News, Guidance, Hot Corp. News, Hot Guidance, Momentum Movers, Short Sales, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
